This means that PDE4 inhibitors such as AN2728 have good therapeutic effects on psoriasis via clear mechanisms, but exactly how AN2728 combined with erythromycin affects purulent skin inflammation caused by S. aureus infection is unknown. The gene discussed is PDE4A; the disease is psoriasis.